- Ariad Pharmaceuticals (ARIA +1.2%) grants Medison Pharma Ltd exclusive rights to commercialize Iclusig (ponatinib) in Israel. Under the terms of the agreement, Medison will be responsible for sales and marketing, medical affairs, regulatory support and pricing/reimbursement approval while Ariad remains the Marketing Authorization Holder.
- Iclusig is currently under regulatory review in Israel. Ariad expects clearance in 2H 2015.
Aria secures Iclusig commercial deal for Israel
From other sites
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 14, 2015)
Video at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs